Your browser is no longer supported. Please, upgrade your browser.
Settings
BOLT [NASD]
Bolt Biotherapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own12.50% Shs Outstand21.50M Perf Week-9.72%
Market Cap421.25M Forward P/E- EPS next Y-2.56 Insider Trans64.73% Shs Float18.60M Perf Month-27.88%
Income- PEG- EPS next Q-0.43 Inst Own87.00% Short Float9.80% Perf Quarter-50.13%
Sales0.07M P/S6287.27 EPS this Y-89.30% Inst Trans0.04% Short Ratio10.43 Perf Half Y-
Book/sh14.11 P/B0.79 EPS next Y-1.60% ROA- Target Price- Perf Year-
Cash/sh7.06 P/C1.58 EPS next 5Y- ROE- 52W Range11.20 - 43.07 Perf YTD-65.32%
Dividend- P/FCF- EPS past 5Y- ROI46.80% 52W High-74.11% Beta-
Dividend %- Quick Ratio22.60 Sales past 5Y- Gross Margin- 52W Low-0.45% ATR0.95
Employees65 Current Ratio22.60 Sales Q/Q- Oper. Margin- RSI (14)26.15 Volatility8.34% 7.08%
OptionableNo Debt/Eq0.00 EPS Q/Q-319.40% Profit Margin- Rel Volume0.83 Prev Close11.86
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume174.72K Price11.15
Recom1.20 SMA20-17.55% SMA50-27.71% SMA200-51.57% Volume144,306 Change-5.99%
Mar-02-21Initiated SVB Leerink Outperform $36
Mar-02-21Initiated Stifel Buy $40
Mar-02-21Initiated Morgan Stanley Overweight $45
Mar-02-21Initiated Guggenheim Buy $42
Jul-20-21 12:42AM  
Jun-22-21 08:16PM  
08:00PM  
06:20PM  
05:33PM  
03:41PM  
02:10PM  
01:03PM  
12:30PM  
12:11PM  
12:00PM  
11:33AM  
11:24AM  
11:00AM  
09:24AM  
08:00AM  
05:22AM  
02:00AM  
Jun-21-21 10:43PM  
08:00PM  
07:36PM  
05:43PM  
04:12PM  
02:25PM  
01:40PM  
01:30PM  
11:30AM  
11:23AM  
11:00AM  
10:25AM  
09:23AM  
05:51AM  
Jun-20-21 03:25PM  
03:00PM  
12:37PM  
03:43AM  
Jun-19-21 08:01PM  
05:16PM  
Jun-18-21 10:50PM  
08:25PM  
06:45PM  
05:57PM  
12:00PM  
11:30AM  
11:28AM  
11:00AM  
07:30AM  
Jun-04-21 09:00AM  
Jun-02-21 08:00AM  
May-13-21 04:05PM  
May-05-21 02:31AM  
Apr-10-21 08:30AM  
Apr-08-21 07:00AM  
Mar-31-21 04:05PM  
Feb-09-21 04:05PM  
Apr-14-20 07:32AM  
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ENGLEMAN EDGARDirectorFeb 09Buy20.00200,0004,000,0001,997,216Feb 09 03:25 PM
Quinn William P.Chief Financial OfficerFeb 09Buy20.001,20024,00013,898Feb 09 03:23 PM
Schatzman Randall CChief Executive OfficerFeb 09Buy20.001,50030,0001,500Feb 09 03:20 PM
Novo Holdings A/S10% OwnerFeb 09Buy20.00400,0008,000,0004,503,991Feb 11 04:39 PM
HEALY JAMESDirectorFeb 09Buy20.00450,0009,000,0002,754,437Feb 09 03:29 PM
Khanna Ashish Siri RamDirectorFeb 09Buy20.001,20024,0001,200Feb 09 03:27 PM
Khanna Ashish Siri RamDirectorFeb 09Buy20.001,00020,0001,000Feb 09 03:27 PM
Vivo Capital VIII, LLC10% OwnerFeb 09Buy20.00350,0007,000,0001,997,216Feb 09 03:37 PM
LAPORTE KATHLEENDirectorFeb 09Buy20.001,20024,0001,200Feb 09 03:35 PM
Sofinnova Venture Partners X, 10% OwnerFeb 09Buy20.00450,0009,000,0002,754,437Feb 09 06:04 PM
Vivo Capital VIII, LLC10% OwnerFeb 09Sale20.002264,520251,522Feb 09 03:37 PM
SHAH MAHENDRADirectorFeb 09Sale20.00621,2401,448,286Feb 09 03:33 PM
ENGLEMAN EDGARDirectorFeb 09Sale20.001643,280251,522Feb 09 03:25 PM